We identify new, early-stage biotechnology companies to join the LIMR incubator, and once on board, offer services to help them launch and succeed.
The companies noted below are integrated directly into LIMR laboratories and office space, share services with LIMR researchers, and oftentimes collaborate with our scientists.
ProstaGene is developing a gene-based, prostate cancer testing technology and a therapeutic for metastatic prostate cancer.
RiboNova, Inc. is developing small molecule drugs against a new family of targets: defective transfer RNAs. Its focus is on therapies that will be used in the treatment of cancer.
Center for Human Antibody Technology (CHAT)
Center for Human Antibody Technology (CHAT) uses a human antibody cloning platform technology developed by LIMR’s Scott Dessain, MD, PhD. CHAT uses this platform along with a state-of-the-art, high throughput antibody production and screening facility, to produce human antibodies for use in the treatment of infectious disease, cancer and neurological illnesses.
For more information, contact Scott Dessain, MD, PhD, at 484.476.6516 or firstname.lastname@example.org.
LIMR Chemical Genomics Center (LCGC)
LIMR Chemical Genomics Center (LCGC) has developed innovative technologies and approaches to catalyze medicinal discovery. We have developed a translational-research framework for public-private partnering called Double-Blinded Drug Discovery (DBD2)®. It aims to connect university and industrial scientists exploring the druggability of emerging medicinal targets.
Our DBD2® approach is a protected open innovation model we designed and put into practice that guards intellectual property rights belonging to each party, while allowing project evolution to achieve specific milestones at an accelerated pace. Our suite of patented ultra-HTS technologies enhance the efficiency of HTS-driven lead discovery research by 500% and has the potential to reveal unexpected pharmacological synergy between drugs and natural products, including nutraceuticals and OTC products.
Because we are a not-for-profit institutional laboratory, our services and resources are made available affordably to enhance the efficiency of HTS-driven lead discovery research for investigators in industry and academia.
For more information, contact Melvin Reichman, PhD, at 484-476-8230 or email@example.com.